Core Viewpoint - Quantum BioPharma Ltd. has strategically increased its cryptocurrency holdings by purchasing an additional USD $1,500,000 worth of Bitcoin and other cryptocurrencies, bringing the total to USD $3,500,000, reflecting the company's belief in the potential of these assets for shareholder returns and as a hedge against the dollar [1][2]. Group 1: Cryptocurrency Investment - The company has received approval from its Board of Directors for the additional cryptocurrency purchase, indicating a strong commitment to this investment strategy [1]. - Quantum BioPharma plans to continue allowing future financings and transactions to be conducted in cryptocurrency, enhancing its financing prospects [2]. - All cryptocurrency holdings are managed by a fully compliant custodian, ensuring adherence to financial and audit regulations [3]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing myelin degradation [4]. - The company retains a 25.71% ownership stake in Celly Nutrition Corp., which is involved in the UNBUZZD™ product line, and is entitled to royalty payments from sales until a total of $250 million is reached [4]. - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by real estate [4].

Core Viewpoint - Quantum BioPharma Ltd. has successfully completed a Phase 1 trial for its compound Lucid-MS, which showed no safety concerns and was well-tolerated in healthy participants, paving the way for future clinical development [1][3][4] Group 1: Trial Results - The final safety review committee found that Lucid-MS was well-tolerated with no serious adverse events reported during the trial [1] - The trial was a Phase 1, randomized, double-blind, placebo-controlled study evaluating the safety and pharmacokinetics of Lucid-21-302 in healthy adult participants [1] Group 2: Product Information - Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound aimed at treating multiple sclerosis (MS) by stabilizing the myelin sheath surrounding nerve fibers [2] - The compound is a patented New Chemical Entity (NCE) that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models [5] Group 3: Future Development Plans - The completion of the Phase 1 trial allows the company to move forward with plans for a Phase 2 trial in MS patients [3][4] - The company aims to achieve drug approval and commercialization of Lucid-MS, focusing on arresting demyelination in MS [4] Group 4: Company Overview - Quantum BioPharma is dedicated to developing innovative solutions for neurodegenerative and metabolic disorders, with a focus on its lead compound, Lucid-MS [5] - The company retains a 25.71% ownership stake in Celly Nutrition, which is involved in the development of unbuzzd™, a product related to its portfolio [5]

Core Viewpoint - Quantum BioPharma Ltd. has engaged MZHCI, LLC to enhance its investor relations and financial communications strategy, focusing on increasing visibility in the investment community and promoting its innovative product pipeline targeting brain disorders and alcohol health [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company dedicated to developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [11]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [11]. Strategic Engagement - MZ will collaborate with Quantum BioPharma's management to create a comprehensive capital markets strategy to boost the company's visibility [2]. - The engagement with MZ is for an initial period of two months at a cost of $10,000 per month, with the option for automatic renewal [8]. Product Focus - Quantum BioPharma is developing products like unbuzzd™ and rekvry™, which utilize innovative technology to address excessive alcohol use, a significant public health issue [3]. - The company is also targeting demyelinating diseases, with multiple sclerosis affecting nearly 1 million people in the U.S. and 2.8 million globally [4]. Revenue Potential - The company sees substantial revenue potential in its focus areas, particularly in addressing unmet needs in brain disorders and alcohol health [5]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition, which markets unbuzzd™, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [11].

Core Viewpoint - Quantum BioPharma Ltd. has engaged Enterprise Canada Inc. and Empire Market Ventures, LLC to enhance its public relations and investor awareness efforts across key markets [1][2][6] Group 1: Engagement of Agencies - The decision to retain the services of Enterprise and Empire was made after a thorough review of available capital [2] - Enterprise has been engaged for an indefinite period starting December 18, 2024, with a structured payment plan totaling C$10,000 for Phase 1 and a monthly retainer of C$5,000 thereafter [3][4] - Empire has been contracted for three months starting February 7, 2025, with a total fee of US$25,000 [5][6] Group 2: Services Provided - Enterprise will assist with public relations strategy, including narrative development, key messaging, and media relationships [4] - Empire will provide investor awareness services, including access to exclusive mailing lists and content creation aimed at increasing investor engagement [6] Group 3: Product Updates - Quantum BioPharma's product unbuzzd™ is a rapid alcohol detoxification beverage, with a ready-to-drink formulation expected to be available in Q1 2025 [7][9] - rekvry™ is designed for alcohol misuse treatment, targeting emergency and hospital settings to reduce healthcare costs [7][9] - LUCID-21-302 is a new chemical entity aimed at treating demyelinating diseases, with an initial focus on multiple sclerosis [8][9] Group 4: Company Overview - Quantum BioPharma is focused on developing innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse [10] - The company retains a 25.71% ownership stake in Celly Nutrition, which markets unbuzzd™, and is entitled to a 7% royalty on sales until reaching $250 million [11]

Core Viewpoint - Quantum BioPharma Ltd. announced that its licensee, Celly Nutrition Corporation, is raising up to $10 million USD and exploring an initial public offering on a major US exchange, which indicates strong market interest in their product unbuzzd, a beverage designed to enhance alcohol metabolism and reduce hangover symptoms [1][3][4]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse [5]. - The company retains a 25.71% ownership stake in Celly Nutrition as of June 30, 2024, and has a royalty agreement that includes 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty rate drops to 3% indefinitely [2][5]. Product Details - unbuzzd is a scientifically-backed beverage that accelerates alcohol metabolism, restores mental clarity, and alleviates hangover symptoms, appealing to consumers who wish to enjoy alcohol responsibly [7][8]. - Clinical trials demonstrated that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster than a placebo within 30 minutes, improves alertness, stabilizes heart rate and blood pressure, and significantly reduces hangover symptoms [14]. Strategic Developments - Celly Nutrition has engaged a leading New York investment bank to assist with financial advisory services and to manage a proposed public offering, indicating a strategic move towards expanding its market presence [3][6]. - The CEO of Celly Nutrition emphasized the importance of this capital raise for accelerating marketing and sales development of unbuzzd, reflecting the company's growth strategy [3].

TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolis ...

TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased USD $1,000,000 Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. As well, going forward the Company will allow for future financing and other transactions to be carried out in cryptocurrency. This move reflects the company's belief in t ...